SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-004638
Filing Date
2023-02-27
Accepted
2023-02-27 16:02:27
Documents
14
Period of Report
2023-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvmd-20230227.htm   iXBRL 8-K 53430
2 EX-99.1 rvmd-ex99_1.htm EX-99 298514
3 GRAPHIC img162218922_0.jpg GRAPHIC 5984
  Complete submission text file 0000950170-23-004638.txt   495194

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvmd-20230227.xsd EX-101.SCH 2502
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvmd-20230227_pre.xml EX-101.PRE 9922
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvmd-20230227_lab.xml EX-101.LAB 13474
8 EXTRACTED XBRL INSTANCE DOCUMENT rvmd-20230227_htm.xml XML 4756
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

IRS No.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39219 | Film No.: 23674660
SIC: 2836 Biological Products, (No Diagnostic Substances)